← All trials
NCT06809140
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2025
- Primary completion
- Nov 30, 2027
- Completion date
- Nov 30, 2029
- First posted
- Feb 5, 2025
- Last posted
- Feb 20, 2025
- Enrollment
- 47
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hoosier Cancer Research NetworkLead sponsor
- Hoosier Cancer Research NetworkSponsor investigator
- Icahn School of Medicine at Mount SinaiCollaborator
- AstellasCollaborator
- MerckCollaborator
- Seattle GeneticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.